Emergence of invasive pneumococcal disease caused by non-vaccine serotypes in the era of the 7-valent conjugate vaccine

被引:5
|
作者
Gonzalez Martinez, F. [1 ]
Navarro Gomez, M. L. [1 ]
Saavedra Lozano, J. [1 ]
Santos Sebastian, M. M. [1 ]
Rodriguez Fernandez, R. [1 ]
Gonzalez Sanchez, M. [1 ]
Cercenado Mansilla, E. [2 ]
Hernandez-Sampelayo Matos, T. [1 ]
机构
[1] Hosp Infantil Univ Gregorio Maranon, Dept Pediat, Secc Infectol Pediat, Madrid, Spain
[2] Hosp Infantil Univ Gregorio Maranon, Serv Microbiol, Madrid, Spain
来源
ANALES DE PEDIATRIA | 2014年 / 80卷 / 03期
关键词
Invasive pneumococcal disease; Emerging serotypes; Heptavalent pneumococcal conjugate vaccine; STREPTOCOCCUS-PNEUMONIAE; NONVACCINE SEROTYPES; UNITED-STATES; BASQUE COUNTRY; CHILDREN; SPAIN; EPIDEMIOLOGY; POPULATION; INFECTIONS; SAFETY;
D O I
10.1016/j.anpedi.2013.05.003
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction: There has been an increased incidence in invasive pneumococcal disease (IPD) produced by non-vaccine serotype (NVS) of Streptococcus pneumoniae after the introduction of PCV7. Our objective was to describe the epidemiological, clinical and microbiological characteristics of IPD caused by NVS in a tertiary hospital in Madrid. Patients and methods: Retrospective (1998-2004) and prospective (2005-2009) study evaluating IPD caused by NVS in children. The study was divided into three periods: P1(1998-2001) when PCV7 was not commercialized; P2 (2002-2005) with 40% vaccine coverage among children; and P3 (2006-2009) when the vaccine was added to the Childhood Immunization Schedule in Madrid. Results: We analyzed 155 cases of IPD. One hundred and fifty of these isolates were serotyped (100 were NVS). There was an increase in the prevalence of IPD from P1(31%) to P2 (54%) and P3 (91%). The most relevant emerging serotypes were 19A, 7 F, 1, 5, 3 and 15C. The most significant clinical syndromes produced by some specific serotypes were as follows: lower respiratory tract infection (LRTI) by serotypes 1, 3, 5 and 15C; LRTI, primary bacteremia and meningitis by serotype 19A; and primary bacteremia by serotype 7F (66%). The large majority (83.8%) of NVS were sensitive to penicillin. Conclusions: There has been an increased prevalence of IPD caused by NVS since the introduction of PCV7. These changes should prompt the introduction of new pneumococcal vaccines, which include most of the NVS, in the childhood immunization calendar to prevent IPD in children. (C) 2012 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:173 / 180
页数:8
相关论文
共 50 条
  • [21] A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada
    Lebel, MH
    Kellner, JD
    Ford-Jones, EL
    Hvidsten, K
    Wang, ECY
    Ciuryla, V
    Arikian, S
    Casciano, R
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (03) : 259 - 268
  • [22] Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands
    Vissers, Marloes
    Wijmenga-Monsuur, Alienke J.
    Knol, Mirjam J.
    Badoux, Paul
    van Houten, Marlies A.
    van der Ende, Arie
    Sanders, Elisabeth A. M.
    Rots, Nynke Y.
    [J]. PLOS ONE, 2018, 13 (03):
  • [24] Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine
    Frenck, Robert, Jr.
    Thompson, Allison
    Yeh, Sylvia H.
    London, Arnold
    Sidhu, Mohinder S.
    Patterson, Scott
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    Gurtman, Alejandra
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (12) : 1086 - 1091
  • [25] Pneumococcal invasive isolates of non-vaccine serotypes in Italy, 1999-2003 (pre-vaccine era)
    Gherardi, G.
    Monaco, M.
    Camilli, R.
    D'Ambrosio, F.
    D'Ancona, P.
    Manganelli, R.
    Dicuonzo, G.
    Pantosti, A.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S265 - S265
  • [26] Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia
    Burgos, J.
    Falco, V.
    Borrego, A.
    Sorde, R.
    Larrosa, M. N.
    Martinez, X.
    Planes, A. M.
    Sanchez, A.
    Palomar, M.
    Rello, J.
    Pahissa, A.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (04) : 385 - 391
  • [27] Changing characteristics of invasive pneumococcal disease in metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine
    Albrich, W. C.
    Baughman, W.
    Schmotzer, B.
    Farley, M. M.
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (12) : 1569 - 1576
  • [28] SEROTYPE-SPECIFIC TRANSMISSION DYNAMICS OF INVASIVE PNEUMOCOCCAL DISEASE AFTER VACCINATION WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
    Snedecor, S. J.
    Botteman, M. F.
    Strutton, D. R.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A393 - A393
  • [29] Invasive pneumococcal infection despite 7-valent conjugated vaccine
    Joye, Sebastien
    Gao, Anja
    Kayemba-Kay's, Simon
    Cotting, Jacques
    Perez, Marie-Helene
    [J]. CLINICS AND PRACTICE, 2013, 3 (01) : 27 - 29
  • [30] A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
    Htar, Myint Tin Tin
    Madhava, Harish
    Balmer, Paul
    Christopoulou, Dina
    Menegas, Damianos
    Bonnet, Eric
    [J]. ADVANCES IN THERAPY, 2013, 30 (08) : 748 - 762